Catalyst Biosciences Profit Margin

The latest profit margin for CBIO is 421.62% as of June 2026. That compares with 13.75% in the prior-year period — up 2966.8% year over year. That is above the Healthcare sector average of 10.58%. Investors often review this figure alongside Catalyst Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, CBIO's profit margin moved from 13.75% to 421.62% — a 2966.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Catalyst Biosciences's valuation or profitability profile.

Against Healthcare companies, CBIO currently prints 421.62% for profit margin, while the sector average sits near 10.58%. That is roughly 3884.9% above the sector mean. Large gaps often invite a closer look at Catalyst Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Catalyst Biosciences converts resources into returns. At 421.62%, CBIO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 13.75% in the prior-year period — up 2966.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CBIO's profit margin (421.62%), review year-over-year change from 13.75%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.